Patents Assigned to United Therapeutic Corporation
  • Treprostinil administration by inhalation
    Patent number: 11357782
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: June 14, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • SALTS OF TREPROSTINIL
    Publication number: 20220153675
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh BATRA, Vijay SHARMA, Sanmin YANG, Yi ZHANG
  • INHALED IMATINIB FOR PULMONARY HYPERTENSION
    Publication number: 20220152025
    Abstract: Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.
    Type: Application
    Filed: November 16, 2021
    Publication date: May 19, 2022
    Applicants: United Therapeutics Corporation, MannKind Corporation
    Inventors: Adam Marc Silverstein, Patrick Poisson, Ajay Keshava, John J. Freeman,, JR., James Mills
  • Compounds and methods for delivery of prostacyclin analogs
    Patent number: 11292758
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: April 5, 2022
    Assignee: United Therapeutics Corporation
    Inventor: Ken Phares
  • TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS
    Publication number: 20220062210
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 3, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Salts of treprostinil
    Patent number: 11236035
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: February 1, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay Sharma, Sanmin Yang, Yi Zhang
  • COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
    Publication number: 20220024845
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: United Therapeutics Corporation
    Inventor: Ken PHARES
  • Synthesis of intermediates for producing prostacyclin derivatives
    Patent number: 11225452
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin. The methods include heating the compound of Formula 2 at a temperature of 180° C. to 185° C. Wherein the heating comprises irradiating the compound of formula 2 with microwave radiation.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: January 18, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • TREPROSTINIL ADMINISTRATION BY INHALATION
    Publication number: 20220008436
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 13, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • PRODRUGS OF TREPROSTINIL
    Publication number: 20210378996
    Abstract: Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.
    Type: Application
    Filed: June 8, 2021
    Publication date: December 9, 2021
    Applicants: United Therapeutics Corporation, MannKind Corporation
    Inventors: Hitesh BATRA, Liang GUO, Patrick POISSON, Sri Harsha TUMMALA, Elizabeth Ann HARRIS
  • SYNTHESIS OF ESUBERAPROST PRODRUGS
    Publication number: 20210355095
    Abstract: Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: October 17, 2019
    Publication date: November 18, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh BATRA, Liang GUO
  • TREATMENT FOR INTERSTITIAL LUNG DISEASE
    Publication number: 20210330621
    Abstract: Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 28, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Leigh Peterson, Peter Smith, Chunqin Deng
  • CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS
    Publication number: 20210317066
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Application
    Filed: May 10, 2021
    Publication date: October 14, 2021
    Applicant: United Therapeutics Corporation
    Inventor: Peter LAING
  • Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
    Patent number: 11141393
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 12, 2021
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • INHALATION FORMULATIONS OF TREPROSTINIL
    Publication number: 20210177787
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 17, 2021
    Applicant: United Therapeutics Corporation
    Inventor: Michael WADE
  • SALTS OF TREPROSTINIL
    Publication number: 20210179528
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: November 30, 2020
    Publication date: June 17, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh BATRA, Vijay SHARMA, Sanmin YANG, Yi ZHANG
  • EXTRACELLULAR VESICLES AND THEIR USES
    Publication number: 20210169939
    Abstract: Provided are methods for isolating potent extracellular vesicle populations from mesenchymal stem cells. In particular, the present disclosure identified a protein profile specific for MSC-derived EV populations. Moreover, disclosed herein is the use of the isolated extracellular vesicles in treating a variety of diseases and conditions, including chronic or acute lung diseases such as pulmonary hypertension, ARDS and diseases and conditions characterized by vasculopathy, reduced angiogenesis, apoptosis, mitochondrial dysfunction, acute inflammation, fibrosis, or chronic inflammation.
    Type: Application
    Filed: December 2, 2020
    Publication date: June 10, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Roger Ilagan, Sarah Hogan, John Cheadle, Carolina Papu
  • EXTRACELLULAR VESICLES WITH ENHANCED POTENCY
    Publication number: 20210154238
    Abstract: Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 27, 2021
    Applicant: United Therapeutics Corporation
    Inventors: Sarah HOGAN, Roger Marquez ILAGAN, Maria Pia RODRIGUEZ, Carolina MEDRANO, John CHEADLE
  • METHOD FOR PURIFYING ANTIBODIES
    Publication number: 20210139535
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Application
    Filed: January 21, 2021
    Publication date: May 13, 2021
    Applicants: United Therapeutics Corporation, The United States of America as Represented by the Secretary, Department of Health & Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Controlled release pharmaceutical formulations
    Patent number: 11001551
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: May 11, 2021
    Assignee: United Therapeutics Corporation
    Inventor: Peter Laing